Evelyn Kurt-Jones to Antiviral Agents
This is a "connection" page, showing publications Evelyn Kurt-Jones has written about Antiviral Agents.
Connection Strength
0.638
-
Chang CW, Parsi KM, Somasundaran M, Vanderleeden E, Liu P, Cruz J, Cousineau A, Finberg RW, Kurt-Jones EA. A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants. Viruses. 2022 06 23; 14(7).
Score: 0.161
-
Shirey KA, Lai W, Patel MC, Pletneva LM, Pang C, Kurt-Jones E, Lipsky M, Roger T, Calandra T, Tracey KJ, Al-Abed Y, Bowie AG, Fasano A, Dinarello CA, Gusovsky F, Blanco JC, Vogel SN. Novel strategies for targeting innate immune responses to influenza. Mucosal Immunol. 2016 09; 9(5):1173-82.
Score: 0.103
-
Hendricks GL, Velazquez L, Pham S, Qaisar N, Delaney JC, Viswanathan K, Albers L, Comolli JC, Shriver Z, Knipe DM, Kurt-Jones EA, Fygenson DK, Trevejo JM, Wang JP, Finberg RW. Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses. Antiviral Res. 2015 Apr; 116:34-44.
Score: 0.096
-
MacKay CR, Wang JP, Kurt-Jones EA. Dicer's role as an antiviral: still an enigma. Curr Opin Immunol. 2014 Feb; 26:49-55.
Score: 0.089
-
Renzette N, Caffrey DR, Zeldovich KB, Liu P, Gallagher GR, Aiello D, Porter AJ, Kurt-Jones EA, Bolon DN, Poh YP, Jensen JD, Schiffer CA, Kowalik TF, Finberg RW, Wang JP. Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro. J Virol. 2014 Jan; 88(1):272-81.
Score: 0.088
-
Hendricks GL, Weirich KL, Viswanathan K, Li J, Shriver ZH, Ashour J, Ploegh HL, Kurt-Jones EA, Fygenson DK, Finberg RW, Comolli JC, Wang JP. Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus. J Biol Chem. 2013 Mar 22; 288(12):8061-8073.
Score: 0.084
-
Zhou S, Cerny AM, Bowen G, Chan M, Knipe DM, Kurt-Jones EA, Finberg RW. Discovery of a novel TLR2 signaling inhibitor with anti-viral activity. Antiviral Res. 2010 Sep; 87(3):295-306.
Score: 0.018